{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:19:32Z","timestamp":1761059972118,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bcmd.2015.07.011","type":"journal-article","created":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T11:37:20Z","timestamp":1437219440000},"page":"281-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Calreticulin mutation burden \u2014 Is it a stable clone in patients with essential thrombocythemia and myelofibrosis?"],"prefix":"10.1016","volume":"55","author":[{"given":"Yulia","family":"Shuly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meital","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lior","family":"Ben-Asaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Kneller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninette","family":"Amariglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ophira","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2015.07.011_bb0005","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.07.011_bb0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.07.011_bb0015","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.011_bb0020","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.07.011_bb0025","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.07.011_bb0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-015-0351-8","article-title":"Ruxolitinib: a review of its use in patients with myelofibrosis","volume":"75","author":"Plosker","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.bcmd.2015.07.011_bb0035","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"Andrikovics","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2015.07.011_bb0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000366263","article-title":"Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK-2 negative myeloproliferative neoplasms","volume":"133","author":"Wojtaszewska","year":"2015","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bcmd.2015.07.011_bb0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for myelofibrosis research and treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.011_bb0050","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.07.011_bb0055","first-page":"544","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"1231","author":"Rumi","year":"2014","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:31:09Z","timestamp":1761049869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979615001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1079979615001394"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.07.011","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calreticulin mutation burden \u2014 Is it a stable clone in patients with essential thrombocythemia and myelofibrosis?","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}